Literature DB >> 25224811

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats.

Alexandra Sporková1, Sárka Jíchová, Zuzana Husková, Libor Kopkan, Akira Nishiyama, Sung H Hwang, Bruce D Hammock, John D Imig, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Herbert J Kramer, Luděk Cervenka.   

Abstract

Recent studies have shown that the long-term antihypertensive action of soluble epoxide hydrolase inhibition (sEH) in angiotensin-II (AngII)-dependent hypertension might be mediated by the suppression of intrarenal AngII levels. To test this hypothesis, we examined the effects of acute (2 days) and chronic (14 days) sEH inhibition on blood pressure (BP) in transgenic rats with inducible AngII-dependent hypertension. AngII-dependent malignant hypertension was induced by 10 days' dietary administration of indole-3-carbinol (I3C), a natural xenobiotic that activates the mouse renin gene in Cyp1a1-Ren-2 transgenic rats. BP was monitored by radiotelemetry. Acute and chronic sEH inhibition was achieved using cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid, given at doses of 0.3, 3, 13, 26, 60 and 130 mg/L in drinking water. At the end of experiments, renal concentrations of epoxyeicosatrienoic acids, their inactive metabolites dihydroxyeicosatrienoic acids and AngII were measured. Acute BP-lowering effects of sEH inhibition in I3C-induced rats was associated with a marked increase in renal epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids ratio and acute natriuresis. Chronic treatment with cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced rats elicited dose-dependent persistent BP lowering associated with a significant reduction of plasma and kidney AngII levels. Our findings show that the acute BP-lowering effect of sEH inhibition in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated by a substantial increase in intrarenal epoxyeicosatrienoic acids and their natriuretic action without altering intrarenal renin-angiotensin system activity. Long-term antihypertensive action of cis-4-(4-(3-adamantan-1-yl-ureido)cyclohexyloxy) benzoic acid in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated mostly by suppression of intrarenal AngII concentration.
© 2014 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  angiotensin-II; cytochrome P-450 epoxygenase; eicosanoids; epoxyeicosatrienoic acids; hypertension; soluble epoxide hydrolase

Mesh:

Substances:

Year:  2014        PMID: 25224811      PMCID: PMC4347520          DOI: 10.1111/1440-1681.12310

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  45 in total

Review 1.  Current successes and limitations of using genetic modification for blood pressure research.

Authors:  Linda Jane Mullins; John Mullins
Journal:  Pflugers Arch       Date:  2002-11-12       Impact factor: 3.657

Review 2.  Cytochrome P-450 metabolites in renal circulation and excretion--interaction with the nitric oxide (NO) system.

Authors:  E Kompanowska-Jezierska; M Kuczeriszka
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

Review 3.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

4.  Unraveling the Mystery of Goldblatt Hypertension.

Authors:  L. Gabriel Navar; Lixian Zou; Annette Von Thun; Chi Tarng Wang; John D. Imig; Kenneth D. Mitchell
Journal:  News Physiol Sci       Date:  1998-08

Review 5.  Epoxyeicosatrienoic acids and endothelium-dependent responses.

Authors:  William B Campbell; Ingrid Fleming
Journal:  Pflugers Arch       Date:  2010-03-12       Impact factor: 3.657

Review 6.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

7.  Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats.

Authors:  Zuzana Husková; Zdenka Vanourková; Michaela Erbanová; Monika Thumová; Martin Opocenský; John J Mullins; Herbert J Kramer; Marcela Bürgelová; Ludek Cervenka
Journal:  J Hypertens       Date:  2010-03       Impact factor: 4.844

8.  Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.

Authors:  Jing Li; Mairead A Carroll; Praveen N Chander; John R Falck; Bhavani Sangras; Charles T Stier
Journal:  Front Biosci       Date:  2008-05-01

Review 9.  Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension.

Authors:  Jorge Capdevila; Wenhui Wang
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-03       Impact factor: 2.894

10.  Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells.

Authors:  Edson F Nogueira; Claudia A Vargas; Mélissa Otis; Nicole Gallo-Payet; Wendy B Bollag; William E Rainey
Journal:  J Mol Endocrinol       Date:  2007-12       Impact factor: 5.098

View more
  7 in total

Review 1.  Epoxyeicosanoids in hypertension.

Authors:  J D Imig
Journal:  Physiol Res       Date:  2019-09-02       Impact factor: 1.881

2.  Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

Authors:  P Kala; L Sedláková; P Škaroupková; L Kopkan; Z Vaňourková; M Táborský; A Nishiyama; S H Hwang; B D Hammock; J Sadowski; V Melenovský; J D Imig; L Červenka
Journal:  Physiol Res       Date:  2018-03-12       Impact factor: 1.881

3.  1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor, lowers L-NAME-induced hypertension through suppression of angiotensin-converting enzyme in rats.

Authors:  I A Bukhari; B I Alorainey; A A Al-Motrefi; A Mahmoud; W B Campbell; B D Hammock
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-08       Impact factor: 3.507

4.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

5.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

6.  Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats.

Authors:  Šárka Vacková; Libor Kopkan; Soňa Kikerlová; Zuzana Husková; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Bruce D Hammock; John D Imig; Miloš Táborský; Vojtěch Melenovský; Luděk Červenka
Journal:  Front Pharmacol       Date:  2019-01-23       Impact factor: 5.810

7.  Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats.

Authors:  Agnieszka Walkowska; Luděk Červenka; John D Imig; John R Falck; Janusz Sadowski; Elżbieta Kompanowska-Jezierska
Journal:  Front Physiol       Date:  2021-01-28       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.